Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OZ4J
|
|||
| Former ID |
DIB004554
|
|||
| Drug Name |
RG-7446
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Urothelial carcinoma [ICD-11: 2C92.0] | Approved | [1] | |
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 3 | [2] | ||
| Company |
Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034572) | |||
| REF 3 | PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.